(2S)-N6,N6,2-三甲基-1,2-二氢-1,3,5-三嗪-4,6-二胺

Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.